Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc

Bullboard Posts

Post by silvarlineon Aug 06, 2012 12:25am

233 Views

Post# 20186963

Truth Seeker

What was the patent application number .... or was that intentionally missed in your post (dummy)?

Let's be clear .... what patent application are you referring too?

I recall Bill mentioning (at the AGM) a new patent application (enhancement to original LumiSort patent).

The (LumiSort) Patent 8,004,661 appears to be good standing, application 12/495,406,

Transaction History

Date	Transaction Description
08-23-2011	Recordation of Patent Grant Mailed
08-04-2011	Email Notification
08-03-2011	Issue Notification Mailed
08-23-2011	Patent Issue Date Used in PTA Calculation
07-14-2011	Dispatch to FDC
07-12-2011	Application Is Considered Ready for Issue
07-08-2011	Issue Fee Payment Verified
07-08-2011	Issue Fee Payment Received
06-27-2011	Email Notification